FDA Opens Extra-Regulatory Enforcement Door On Vinpocetine – CRN, NPA
This article was originally published in The Rose Sheet
Executive Summary
The Council for Responsible Nutrition and the Natural Products Association argue in comments that FDA would establish a process for removing ingredients from the marketplace outside its regulatory authority if it follows on its proposal to remove vinpocetine, currently widely used in supplements.
You may also be interested in...
FDA Prioritizes Vinpocetine Decison After Animal Study Shows 'Developmental Toxicity'
Agency announces plan in statement by two deputy commissioners warning consumers about safety concerns regarding the semi-synthetic derivative of vincamine, "specifically concerns about the use of this ingredient by women of childbearing age." Recent findings by NIH National Toxicology Program's study with rats and rabbits indicate "vinpocetine may cause a miscarriage or harm fetal development," FDA says.
FTC Could Open Arms For Health Claim Science In Regulatory Review
FTC is implementing Trump administration directives on "eliminating wasteful, unnecessary regulations and processes," but attempting to reduce regulated industries' compliance burden is not the same as slowing FTC enforcement against false and misleading advertising, attorneys say.
FDA Guidance Makes Vinpocetine Compliant Despite Ban Proposal – NPA
NPA CEO Daniel Fabricant says some vinpocetine product marketers don't realize the ingredient's status as an active moiety of a botanical long used in the food supply, a knowledge gap obscures that FDA is using an extra-regulatory procedure to remove vinpocetine.